BRPI0413381A - composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas - Google Patents

composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas

Info

Publication number
BRPI0413381A
BRPI0413381A BRPI0413381-1A BRPI0413381A BRPI0413381A BR PI0413381 A BRPI0413381 A BR PI0413381A BR PI0413381 A BRPI0413381 A BR PI0413381A BR PI0413381 A BRPI0413381 A BR PI0413381A
Authority
BR
Brazil
Prior art keywords
compositions
eyes
manufacture
processes
therapeutic compounds
Prior art date
Application number
BRPI0413381-1A
Other languages
English (en)
Inventor
Joseph G Vehige
James N Chang
Richard Graham
Robert T Lyons
Teresa H Kuan
Chin-Ming Chang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413381(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0413381A publication Critical patent/BRPI0413381A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçõES PARA LIBERAçãO DE COMPOSTOS TERAPêUTICOS NOS OLHOS E PROCESSOS PARA FABRICAçãO E USO DAS MESMAS". A presente invenção refere-se composições para administração de uma quantidade terapeuticamente efetiva de um componente terapêutico. As composições podem incluir um componente veículo oftalmicamente efetivo; uma quantidade terapeuticamente efetiva de um componente terapêutico; e um componente de retenção que pode ser efetivo para reduzir capacidade de umedecimento, induzir viscosidade, aumentar muco - adesão, aumento de altura de menisco sobre uma córnea de um olho e/ou aumento de aposição física a uma córnea de um olho de uma composição.
BRPI0413381-1A 2003-08-07 2004-08-05 composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas BRPI0413381A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49318803P 2003-08-07 2003-08-07
US49317803P 2003-08-07 2003-08-07
PCT/US2004/025540 WO2005014046A2 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes and methods for making and using the same

Publications (1)

Publication Number Publication Date
BRPI0413381A true BRPI0413381A (pt) 2006-10-17

Family

ID=34138742

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413381-1A BRPI0413381A (pt) 2003-08-07 2004-08-05 composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas

Country Status (12)

Country Link
US (4) US8512717B2 (pt)
EP (2) EP2113246B1 (pt)
JP (1) JP2007501799A (pt)
AT (1) ATE444732T1 (pt)
AU (1) AU2004263149B2 (pt)
BR (1) BRPI0413381A (pt)
CA (1) CA2534484A1 (pt)
DE (1) DE602004023516D1 (pt)
DK (1) DK1654002T4 (pt)
ES (2) ES2332049T5 (pt)
PL (1) PL1654002T5 (pt)
WO (1) WO2005014046A2 (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6554424B1 (en) * 1999-03-01 2003-04-29 Boston Innovative Optices, Inc. System and method for increasing the depth of focus of the human eye
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US7628810B2 (en) * 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050046794A1 (en) * 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
ES2332049T5 (es) 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
JP4933897B2 (ja) * 2004-11-05 2012-05-16 千寿製薬株式会社 眼内移行性促進水性点眼剤
US7976577B2 (en) 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
WO2007075720A2 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
EP2464311B1 (en) 2009-08-13 2017-11-15 AcuFocus, Inc. Masked intraocular implants and lenses
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
SI2586426T1 (sl) 2009-12-03 2015-11-30 Alcon Research Ltd. Suspenzije nanodelcev, ki vsebujejo karboksivinilni polimer
RU2452478C1 (ru) * 2011-02-21 2012-06-10 Общество с ограниченной ответственностью "Научно-производственная компания Уралбиофарм" Многофункциональный раствор для эпибульбарных инстилляций
ES2761866T3 (es) 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
CA2857306C (en) 2011-12-02 2017-07-25 Acufocus, Inc. Ocular mask having selective spectral transmission
ES2543182T3 (es) 2012-07-24 2015-08-17 Scan Coin Ab Dispensadores para aparatos de manipulación de monedas
EP2690607B1 (en) 2012-07-24 2024-03-27 Scan Coin Ab Apparatus, method and computer program for flexible dispensing of coins in a coin handling apparatus
EP2690604B1 (en) 2012-07-24 2021-05-26 Scan Coin Ab Coin deposit and dispensing apparatus
EP4265236A3 (en) 2012-07-26 2023-11-29 Allergan, Inc. Dual cap system for container-closures to maintain tip sterility during shelf storage
EA029707B1 (ru) 2012-11-16 2018-05-31 Калитера Байосайенсиз, Инк. Гетероциклические ингибиторы глютаминазы
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
BR112016014404A2 (pt) * 2013-12-18 2017-08-08 Gnt Llc Composições e métodos para tratamento de glaucoma
AU2015274361B2 (en) 2014-06-13 2020-11-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EA037738B1 (ru) 2014-08-07 2021-05-17 Калитера Байосайенсиз, Инк. Кристаллические формы ингибиторов глутаминазы
EP3180332B1 (en) 2014-08-13 2021-10-27 Eolas Therapeutics Inc. Difluoropyrrolidines as orexin receptor modulators
PL3267984T4 (pl) 2015-03-10 2022-05-02 Aurigene Discovery Technologies Limited Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory
MX2017016868A (es) 2015-06-23 2018-09-06 Calithera Biosciences Inc Composiciones y metods para inhibir actividad de arginasa.
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
KR102434308B1 (ko) 2015-10-30 2022-08-19 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
EP3377512A4 (en) 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. NUCLEIC ACID PRODRUGS
AU2017217931B2 (en) 2016-02-12 2020-10-22 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
WO2017210565A1 (en) 2016-06-03 2017-12-07 Prisident And Fellows Of Harvard College Antifungal compounds
WO2018031973A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
IL264664B2 (en) 2016-08-19 2023-03-01 Orasis Pharmaceuticals Ltd Ophthalmic pharmaceutical preparations and uses related to them
US10980767B2 (en) 2016-09-09 2021-04-20 The Regents Of The University Of California Estrogen receptor ligands, compositions and methods related thereto
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
EP4275759A3 (en) 2016-09-26 2024-01-17 Dana-Farber Cancer Institute, Inc. Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
KR20190104521A (ko) 2016-11-08 2019-09-10 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 억제제 병용 요법들
ES2881395T3 (es) 2016-12-22 2021-11-29 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa
JP2020511424A (ja) 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害としての縮合複素環式化合物
MX2019010096A (es) 2017-02-24 2020-01-09 Merck Patent Gmbh Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2018223032A1 (en) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
WO2019073399A1 (en) 2017-10-11 2019-04-18 Aurigene Discovery Technologies Limited CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EA202090749A1 (ru) 2017-11-06 2020-08-19 Ориджен Дискавери Текнолоджис Лимитед Способы совместной терапии для иммуномодуляции
BR112020012476A2 (pt) 2017-12-22 2020-11-24 Medimmune Limited moduladores de moléculas pequenas do domínio btb de keap1
EP3765460A1 (en) 2018-03-14 2021-01-20 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US20220106325A1 (en) 2018-07-27 2022-04-07 California Institute Of Technology Cdk inhibitors and uses thereof
CA3111217A1 (en) 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
JP2022512824A (ja) 2018-10-26 2022-02-07 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
JP2022515293A (ja) 2018-12-10 2022-02-17 ザ ジェネラル ホスピタル コーポレイション クロモリンエステルおよびそれらの使用
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
AU2020234033B2 (en) 2019-03-14 2023-07-13 Astrazeneca Ab Lanabecestat for weight loss
WO2020246503A1 (ja) 2019-06-03 2020-12-10 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法
IL292965A (en) 2019-11-12 2022-07-01 Genzyme Corp Heteroarylaminosulfonamides with 6 positions and methods of using them
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
KR20210076875A (ko) 2019-12-16 2021-06-24 주식회사 스마틴바이오 신생혈관형성인자의 억제를 위한 화합물 및 그 용도
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
CA3230259A1 (en) 2021-09-03 2023-03-09 Junkai Liao Indole compounds and methods of use
US20230124705A1 (en) 2021-10-01 2023-04-20 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
AU2022355108A1 (en) 2021-10-01 2024-04-04 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024036098A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1781701A (en) 1928-05-16 1930-11-18 Phillips Morris Godfrey Philip Machine for removing flags and other adhering leaf from the stalks of tobacco leaves
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4474787A (en) * 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
GB2013084B (en) * 1978-01-25 1982-07-28 Alcon Lab Inc Ophthalmic drug dosage
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
GB8500310D0 (en) * 1985-01-07 1985-02-13 Leo Pharm Prod Ltd Pharmaceutical preparation
US6255299B1 (en) * 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
KR950013754B1 (ko) 1987-09-11 1995-11-15 신텍스(미합중국)인코포레이티드 안과용 비스테로이드계 소염제제
US5527893A (en) * 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4861514A (en) * 1988-06-08 1989-08-29 The Drackett Company Compositions containing chlorine dioxide and their preparation
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
CA2063576C (en) * 1989-06-07 1994-01-25 Gail S. Bazzano Slow release vehicles for minimizing skin irritancy of topical compositions
US5045121A (en) * 1989-06-21 1991-09-03 Gte Products Corporation Method for removing carbon from cemented tungsten carbide articles
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4560493A (en) * 1992-07-06 1994-01-31 Hansen Transmissions International Nv Series of gear units
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5382591A (en) 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5648074A (en) * 1993-05-25 1997-07-15 Allergan Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation
WO1995005803A1 (en) * 1993-08-20 1995-03-02 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ES2187533T3 (es) * 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US6294202B1 (en) 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
JP2002539157A (ja) * 1999-03-15 2002-11-19 トラスティーズ オブ ボストン ユニバーシティ 血管新生阻害
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
JP4132599B2 (ja) * 2000-07-07 2008-08-13 日本板硝子株式会社 画像形成装置
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US8008338B2 (en) * 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
ES2332049T5 (es) 2003-08-07 2014-03-27 Allergan, Inc. Composiciones de administración de sustancias terapéuticas en los ojos
WO2005101982A2 (en) 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
ZA200704869B (en) 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
US20070299124A1 (en) * 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20070254841A1 (en) * 2006-01-25 2007-11-01 Ophthalmic Research Associates, Inc. Formulations and methods for treating dry eye
US20080039398A1 (en) * 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
CN101754748A (zh) * 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
ES2399314T3 (es) 2008-04-24 2013-03-27 Allergan, Inc. Gamma lactamas sustituidas como agentes terapeúticos
US20080275118A1 (en) 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Also Published As

Publication number Publication date
EP1654002A2 (en) 2006-05-10
PL1654002T3 (pl) 2010-03-31
ES2332049T5 (es) 2014-03-27
EP2113246B1 (en) 2016-06-22
WO2005014046A2 (en) 2005-02-17
US20210251961A1 (en) 2021-08-19
AU2004263149B2 (en) 2010-08-19
US8512717B2 (en) 2013-08-20
PL1654002T5 (pl) 2014-06-30
DK1654002T3 (da) 2010-02-01
ES2332049T3 (es) 2010-01-25
CA2534484A1 (en) 2005-02-17
AU2004263149A1 (en) 2005-02-17
US8992952B2 (en) 2015-03-31
EP1654002B2 (en) 2014-01-29
DK1654002T4 (da) 2014-02-17
EP1654002B1 (en) 2009-10-07
US20130296396A1 (en) 2013-11-07
WO2005014046A3 (en) 2006-06-01
ES2593113T3 (es) 2016-12-05
EP2113246A1 (en) 2009-11-04
JP2007501799A (ja) 2007-02-01
ATE444732T1 (de) 2009-10-15
DE602004023516D1 (de) 2009-11-19
US20050031697A1 (en) 2005-02-10
US20150164863A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
BRPI0413381A (pt) composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
FI9630U1 (fi) Järjestelmä potilaan silmän verkkokalvon hoitamiseksi laserilla
IS7215A (is) Aðferðir til að meðhöndla nýæðarsjúkdóma í augum
BRPI0715431B8 (pt) materiais de dispositivo otorrinolaringológico e oftálmico de baixa pegajosidade
WO2006039467A3 (en) Biomedical devices containing amphiphilic block copolymers
MXPA05013290A (es) Composiciones oftalmicas que contienen una combinacion sinergistica de dos polimeros.
BR0102582A (pt) Composições de limpeza
MXPA03008401A (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
AR048912A1 (es) Inmunoglobulinas anti-nogo
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
TW200501969A (en) Ophthalmic compositions containing a synergistic combination of three polymers
DK1110554T3 (da) Medicinal præparater til behandling af öjensygdomme
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
EP2062872A3 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2005041870A3 (en) Composition and method for the treatment of eye disease
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
DE602004009166D1 (de) Neue Analoga von Nitrobenzylthioinosin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 47/00; A61P 7/00

Ipc: A61K 47/00 (2011.01), A61P 7/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]